Literature DB >> 2455956

Neurologic sequelae following interferon therapy of juvenile laryngeal papilloma.

T Vesikari1, A Nuutila, K Cantell.   

Abstract

Human leukocyte interferon at doses from 2 million units every two days to 3 million units daily was given to a 2-year-old boy for the treatment of recurrent juvenile laryngeal papilloma. After 7 months of treatment the child developed spastic diplegia, which persisted despite the discontinuation of interferon therapy. The clinical picture was consistent with an upper motor neuron lesion; no evidence of peripheral neuropathy was found.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2455956     DOI: 10.1111/j.1651-2227.1988.tb10718.x

Source DB:  PubMed          Journal:  Acta Paediatr Scand        ISSN: 0001-656X


  9 in total

1.  MR imaging of hepatic hemangiomas of infancy and changes seen with interferon alpha-2a treatment.

Authors:  T Chung; F A Hoffer; P E Burrows; H J Paltiel
Journal:  Pediatr Radiol       Date:  1996

Review 2.  Is some white matter damage in preterm neonates induced by a human pestivirus?

Authors:  O Dammann; A Leviton
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1998-05       Impact factor: 5.747

3.  A Brief Historical Perspective on the Pathological Consequences of Excessive Type I Interferon Exposure In vivo.

Authors:  Yanick J Crow; Pierre Lebon; Jean-Laurent Casanova; Ion Gresser
Journal:  J Clin Immunol       Date:  2018-09-05       Impact factor: 8.317

4.  Juvenile chronic myeloid leukaemia and alpha-interferon.

Authors:  M Aricò; L Nespoli; D Caselli; F Bonetti; F A Porta; G R Burgio
Journal:  Eur J Pediatr       Date:  1989-01       Impact factor: 3.183

5.  Growth retardation as a long-term side-effect of alpha-interferon therapy.

Authors:  K Kikawa; K Nishida; A Tanizawa; Y Shigematsu; A Nakai; M Sudo; T Matsuyama
Journal:  Eur J Pediatr       Date:  1995-07       Impact factor: 3.183

6.  Toxic effect of intraventricular interferon-alpha in subacute sclerosing panencephalitis.

Authors:  C Cianchetti; A L Fratta; F Muntoni; G Marrosu; M G Marrosu
Journal:  Ital J Neurol Sci       Date:  1994-04

Review 7.  Clinical toxicity of the interferons.

Authors:  T Vial; J Descotes
Journal:  Drug Saf       Date:  1994-02       Impact factor: 5.606

8.  Sirolimus for the treatment of children with various complicated vascular anomalies.

Authors:  Herwig Lackner; Anna Karastaneva; Wolfgang Schwinger; Martin Benesch; Petra Sovinz; Markus Seidel; Daniela Sperl; Sofia Lanz; Emir Haxhija; Friedrich Reiterer; Erich Sorantin; Christian E Urban
Journal:  Eur J Pediatr       Date:  2015-06-04       Impact factor: 3.183

Review 9.  The type I interferonopathies: 10 years on.

Authors:  Yanick J Crow; Daniel B Stetson
Journal:  Nat Rev Immunol       Date:  2021-10-20       Impact factor: 108.555

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.